New hope for scarred lungs: global trial tests potential IPF drug
NCT ID NCT07230288
Summary
This study is testing whether a new drug called ABBV-142 can help control Idiopathic Pulmonary Fibrosis (IPF), a serious disease that scars the lungs and makes breathing difficult. About 165 adults with IPF will be randomly assigned to receive either the new drug or a placebo for one year to see if it is safe and can slow the decline in lung function. The study is designed as a 'platform,' meaning different treatments can be tested within the same framework over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital /ID# 278039
RECRUITINGTaichung, 40447, Taiwan
-
Christie Clinic on University /ID# 277871
RECRUITINGChampaign, Illinois, 61820, United States
-
Sec Clinical Research - East - Dothan - Graceland /ID# 278328
RECRUITINGDothan, Alabama, 36305, United States
Conditions
Explore the condition pages connected to this study.